Buprenorphine or Methadone Treatment

PreclinicalSmall molecule

Buprenorphine or Methadone Treatment is one of 37 small molecule programs targeting Opioid Use Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Opioid Use DisorderActive, not recruiting

Opioid Use DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

47 competitors in Opioid Use Disorder

#DrugCompanyPhaseTrials

Suboxone

IIndivior Inc.

Approved

21 2

Sovaldi

Gilead

Approved

1 3

Dolophine

HHikma Pharmaceuticals LLC

Approved

6 4

Cabenuva

Oxycontin

3 6

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

3 7

MS Contin

HHikma Pharmaceuticals LLC

Approved

2 8

Lucemyra

BBioCorRx Pharmaceuticals Inc

Approved

2 9

Narcan

SScienture

Approved

2 10

Marcaine

IInnocoll

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Opioid Use Disorder1 trial

Multimodal Fetal and Placental Imaging and Biomarkers of Clinical Outcomes in Opioid Use Disorder

Enrolling by invitation·IIndiana University··NCT06415994·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Buprenorphine or Methadone Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Buprenorphine or Methadone Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Buprenorphine or Methadone Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indiana University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IIndiana University

Buprenorphine or Methadone Treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Opioid Use Disorder1 trial

References

Drug Info

Quick Facts

Related News